Last reviewed · How we verify
A+C+hib Conjugate Vaccine
A conjugate vaccine that combines antigens from meningococcus serogroups A and C with Haemophilus influenzae type b (Hib) to stimulate immune responses against these bacterial pathogens.
A conjugate vaccine that combines antigens from meningococcus serogroups A and C with Haemophilus influenzae type b (Hib) to stimulate immune responses against these bacterial pathogens. Used for Prevention of meningococcal disease caused by Neisseria meningitidis serogroups A and C, Prevention of invasive Haemophilus influenzae type b disease.
At a glance
| Generic name | A+C+hib Conjugate Vaccine |
|---|---|
| Sponsor | Jiangsu Province Centers for Disease Control and Prevention |
| Drug class | Conjugate vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
The vaccine uses polysaccharide antigens from Neisseria meningitidis serogroups A and C and from Haemophilus influenzae type b, conjugated to a protein carrier to enhance immunogenicity. This conjugation improves T-cell dependent immune responses, particularly in infants and young children, generating both antibody and cellular immunity against these three major bacterial meningitis and invasive disease pathogens.
Approved indications
- Prevention of meningococcal disease caused by Neisseria meningitidis serogroups A and C
- Prevention of invasive Haemophilus influenzae type b disease
Common side effects
- Injection site reactions (pain, erythema, swelling)
- Fever
- Irritability
- Drowsiness
Key clinical trials
- A Study on the Immune Response and Safety of a Multicomponent Shigella Vaccine in Preventing Shigellosis in Infants (PHASE2)
- Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa (PHASE3)
- Long-Term Immunogenicity of the altSonflex1-2-3 Shigella Vaccine in African Children (PHASE2)
- A Study on the Safety and Immune Responses to the GVGH altSonflex1-2-3 Vaccine Against Shigellosis in Adults, Children, and Infants (PHASE1)
- A Phase II/III Study to Evaluate the Immunogenicity, Safety and Lot-to-lot Consistency of LBVD, a Fully Liquid Hexavalent Diphtheria-tetanus-whole Cell Pertussis-hepatitis B-poliovirus-Haemophilus Influenzae Type b Conjugate (DTwP-HepB-IPV-Hib) Vaccine, in Healthy Infants as Primary Series (PHASE2, PHASE3)
- A Clinical Trial of Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed(DTcP) (PHASE3)
- Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine When Co-administered With Routine Pediatric Vaccines in Healthy Infants and Toddlers in Europe (PHASE3)
- Immunogenicity of Different Primary Immunization Schedules with Inactivated Poliovirus Vaccine (IPV) Plus Pentavalent Vaccine (DTwP-HBV-Hib) or with Hexavalent Vaccine (DTwP-HBV-Hib-IPV) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: